In the endothelium of patients with CAD and T2D, AMPK may be part of a feedback or adaptive mechanism, wherein elevated mtROS production results in activation of AMPK which, in turn, stimulates protective responses which may contribute towards, but are not solely responsible for, increasing NO bioavailability and attenuating endothelial dysfunction. The gene discussed is PRKAA1; the disease is endothelial dysfunction.